Anthony Caristo, DPM
Foot & Ankle Surgery · Newark, DENPI 1801898143
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Smith+Nephew accounts for 73.1% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $322, 3.6 times the $89 reported in 2019. That places this record below the midpoint for foot & ankle surgery clinicians in DE, where the typical reported total is $3,171.
Across 43 payments — averaging $24.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$780
- Osteomed LLC$136
- Stryker$62
- Paratek Pharmaceuticals, Inc.$61
- Bioventus LLC$27
What the payments were for
- Food & beverage$1,01996%
- Education$474%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 32 | $780 |
| Osteomed LLC | 3 | $136 |
| Stryker(2 entities) | 4 | $62 |
| Paratek Pharmaceuticals, Inc. | 3 | $61 |
| Bioventus LLC | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STRAVIX MESH$146
How this compares
$1,066 in reported general payments places this provider in the 20th percentile of 32 foot & ankle surgery providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 223 | $6,326 |
| Cephalexin | 67 | $472 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 30 | $424 |
| Doxycycline Monohydrate | 21 | $386 |
| Ciprofloxacin Hcl | 25 | $362 |
| Gabapentin | 11 | $349 |
| NystopNystatin | 20 | $282 |
| Nystatin | 16 | $184 |
| Metronidazole | 19 | $146 |
| Methylprednisolone | 21 | $118 |
| NyamycNystatin | 11 | $110 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 13 | $43 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Newark
- Kirstyn UrbasNewark$7K
- Raymond di PretoroNewark$4K
- Jason BellNewark$4K
- Aabha SuchakNewark$2K
- Arij RashidNewark$242
- William NewcombNewark$23
- Jacob HanlonDover$50K
- Cody BowersWilmington$14K
- Brendan KaneLewes$11K
- Bradley LemonSeaford$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.